627 related articles for article (PubMed ID: 25392179)
21. Anti-programmed death-1 and anti-programmed death-ligand 1 antibodies in cancer therapy.
Hamid O; Carvajal RD
Expert Opin Biol Ther; 2013 Jun; 13(6):847-61. PubMed ID: 23421934
[TBL] [Abstract][Full Text] [Related]
22. CTLA-4 and PD-1/PD-L1 blockade: new immunotherapeutic modalities with durable clinical benefit in melanoma patients.
Ott PA; Hodi FS; Robert C
Clin Cancer Res; 2013 Oct; 19(19):5300-9. PubMed ID: 24089443
[TBL] [Abstract][Full Text] [Related]
23. Combined blockade of programmed death-1 and activation of CD137 increase responses of human liver T cells against HBV, but not HCV.
Fisicaro P; Valdatta C; Massari M; Loggi E; Ravanetti L; Urbani S; Giuberti T; Cavalli A; Vandelli C; Andreone P; Missale G; Ferrari C
Gastroenterology; 2012 Dec; 143(6):1576-1585.e4. PubMed ID: 22929808
[TBL] [Abstract][Full Text] [Related]
24. Immune Checkpoint Inhibitors in Gynecological Cancers: Update of Literature and Perspectives of Clinical Research.
Gadducci A; Guerrieri ME
Anticancer Res; 2017 Nov; 37(11):5955-5965. PubMed ID: 29061774
[TBL] [Abstract][Full Text] [Related]
25. T helper responses are maintained by basal-like breast cancer cells and confer to immune modulation via upregulation of PD-1 ligands.
Karasar P; Esendagli G
Breast Cancer Res Treat; 2014 Jun; 145(3):605-14. PubMed ID: 24816762
[TBL] [Abstract][Full Text] [Related]
26. B7-H1 expression on non-small cell lung cancer cells and its relationship with tumor-infiltrating lymphocytes and their PD-1 expression.
Konishi J; Yamazaki K; Azuma M; Kinoshita I; Dosaka-Akita H; Nishimura M
Clin Cancer Res; 2004 Aug; 10(15):5094-100. PubMed ID: 15297412
[TBL] [Abstract][Full Text] [Related]
27. PD-1 blockage delays murine squamous cell carcinoma development.
Belai EB; de Oliveira CE; Gasparoto TH; Ramos RN; Torres SA; Garlet GP; Cavassani KA; Silva JS; Campanelli AP
Carcinogenesis; 2014 Feb; 35(2):424-31. PubMed ID: 24031027
[TBL] [Abstract][Full Text] [Related]
28. Fas ligand and tumour counter-attack in colorectal cancer stratified according to microsatellite instability status.
Michael-Robinson JM; Pandeya N; Cummings MC; Walsh MD; Young JP; Leggett BA; Purdie DM; Jass JR; Radford-Smith GL
J Pathol; 2003 Sep; 201(1):46-54. PubMed ID: 12950016
[TBL] [Abstract][Full Text] [Related]
29. Sensitive detection of PD-L1 expression on circulating epithelial tumor cells (CETCs) could be a potential biomarker to select patients for treatment with PD-1/PD-L1 inhibitors in early and metastatic solid tumors.
Schott DS; Pizon M; Pachmann U; Pachmann K
Oncotarget; 2017 Sep; 8(42):72755-72772. PubMed ID: 29069824
[TBL] [Abstract][Full Text] [Related]
30. Chemopreventive agents induce programmed death-1-ligand 1 (PD-L1) surface expression in breast cancer cells and promote PD-L1-mediated T cell apoptosis.
Zhang P; Su DM; Liang M; Fu J
Mol Immunol; 2008 Mar; 45(5):1470-6. PubMed ID: 17920123
[TBL] [Abstract][Full Text] [Related]
31. PD-L1 (B7-H1) expression by urothelial carcinoma of the bladder and BCG-induced granulomata: associations with localized stage progression.
Inman BA; Sebo TJ; Frigola X; Dong H; Bergstralh EJ; Frank I; Fradet Y; Lacombe L; Kwon ED
Cancer; 2007 Apr; 109(8):1499-505. PubMed ID: 17340590
[TBL] [Abstract][Full Text] [Related]
32. The Controversial Role of PD-1 and Its Ligands in Gynecological Malignancies.
Marinelli O; Annibali D; Aguzzi C; Tuyaerts S; Amant F; Morelli MB; Santoni G; Amantini C; Maggi F; Nabissi M
Front Oncol; 2019; 9():1073. PubMed ID: 31681606
[TBL] [Abstract][Full Text] [Related]
33.
Wieser V; Gaugg I; Fleischer M; Shivalingaiah G; Wenzel S; Sprung S; Lax SF; Zeimet AG; Fiegl H; Marth C
Oncotarget; 2018 Apr; 9(25):17501-17511. PubMed ID: 29707124
[TBL] [Abstract][Full Text] [Related]
34. Correlation between the Expression of PD-L1 and Clinicopathological Parameters in Triple Negative Breast Cancer Patients.
Doğukan R; Uçak R; Doğukan FM; Tanık C; Çitgez B; Kabukcuoğlu F
Eur J Breast Health; 2019 Oct; 15(4):235-241. PubMed ID: 31620682
[TBL] [Abstract][Full Text] [Related]
35. Clear cell ovarian cancers with microsatellite instability: A unique subset of ovarian cancers with increased tumor-infiltrating lymphocytes and PD-1/PD-L1 expression.
Howitt BE; Strickland KC; Sholl LM; Rodig S; Ritterhouse LL; Chowdhury D; D'Andrea AD; Matulonis UA; Konstantinopoulos PA
Oncoimmunology; 2017; 6(2):e1277308. PubMed ID: 28344892
[TBL] [Abstract][Full Text] [Related]
36. The presence of PD-1 positive tumor infiltrating lymphocytes in triple negative breast cancers is associated with a favorable outcome of disease.
Brockhoff G; Seitz S; Weber F; Zeman F; Klinkhammer-Schalke M; Ortmann O; Wege AK
Oncotarget; 2018 Jan; 9(5):6201-6212. PubMed ID: 29464065
[TBL] [Abstract][Full Text] [Related]
37. GBP5 Repression Suppresses the Metastatic Potential and PD-L1 Expression in Triple-Negative Breast Cancer.
Cheng SW; Chen PC; Lin MH; Ger TR; Chiu HW; Lin YF
Biomedicines; 2021 Apr; 9(4):. PubMed ID: 33916322
[TBL] [Abstract][Full Text] [Related]
38. PD-1 and PD-L1 co-expression predicts favorable prognosis in gastric cancer.
Wu Y; Cao D; Qu L; Cao X; Jia Z; Zhao T; Wang Q; Jiang J
Oncotarget; 2017 Sep; 8(38):64066-64082. PubMed ID: 28969052
[TBL] [Abstract][Full Text] [Related]
39. Increased PD-L1 expression in breast and colon cancer stem cells.
Wu Y; Chen M; Wu P; Chen C; Xu ZP; Gu W
Clin Exp Pharmacol Physiol; 2017 May; 44(5):602-604. PubMed ID: 28107571
[TBL] [Abstract][Full Text] [Related]
40. Viral-induced Modulation of Multiple Checkpoint Proteins in Cancers.
Nuovo GJ; Folcik VA; Magro C
Appl Immunohistochem Mol Morphol; 2017 Jul; 25(6):407-414. PubMed ID: 28697066
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
